Get the Stockscreener App
1.66
5.68%
-0.10
Pre-market:
1.64
-0.02
-1.20%
Autolus Therapeutics Plc Adr stock is traded at $1.66, with a volume of 2.77M.
It is down -5.68% in the last 24 hours and up +20.29% over the past month.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
See More
Previous Close:
$1.76
Open:
$1.77
24h Volume:
2.77M
Relative Volume:
0.80
Market Cap:
$441.79M
Revenue:
-
Net Income/Loss:
$-208.38M
P/E Ratio:
-1.3833
EPS:
-1.2
Net Cash Flow:
$-156.57M
1W Performance:
+3.11%
1M Performance:
+20.29%
6M Performance:
+45.61%
1Y Performance:
-59.61%
1-Day Range:
$1.62
$1.79
1-Week Range:
$1.45
$1.80
52-Week Range:
$1.105
$5.00
Autolus Therapeutics Plc Adr Stock (AUTL) Company Profile
Name
Autolus Therapeutics Plc Adr
Sector
Industry
Phone
44 20 3829 6230
Address
THE MEDIAWORKS, LONDON
Compare AUTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUTL
Autolus Therapeutics Plc Adr
|
1.66 | 468.41M | 0 | -208.38M | -156.57M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Autolus Therapeutics Plc Adr Stock (AUTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Upgrade | Goldman | Neutral → Buy |
| Nov-15-24 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Mar-27-23 | Resumed | Wells Fargo | Overweight |
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| Jun-14-21 | Upgrade | Jefferies | Hold → Buy |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | JP Morgan | Overweight |
| Jul-22-20 | Initiated | SunTrust | Buy |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Sep-23-19 | Initiated | Needham | Buy |
| May-17-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-24-18 | Initiated | H.C. Wainwright | Buy |
View All
Autolus Therapeutics Plc Adr Stock (AUTL) Latest News
Analysts Set Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Target Price at $9.12 - Defense World
Wealth Enhancement Advisory Services LLC Sells 548 Shares of SPDR S&P Global Natural Resources ETF $GNR - Defense World
Goldman Sachs Group Inc. Has $78,000 Stock Position in Autolus Therapeutics PLC Sponsored ADR $AUTL - Defense World
Is CVR stock at risk of policy regulationJuly 2025 Earnings & Reliable Trade Execution Plans - newser.com
Short interest data insights for PRMEPortfolio Performance Summary & Community Trade Idea Sharing - newser.com
Will iRobot Corporation see short term momentumBond Market & Smart Investment Allocation Insights - newser.com
Will HVAC stock outperform energy sector in 2025Market Performance Report & High Accuracy Trade Alerts - newser.com
Can Sanyo Chemical Industries Ltd. (XSI) stock reach $200 price target2025 Volatility Report & Fast Entry High Yield Tips - newser.com
What MACD signals say about Funko Inc.2025 Volume Leaders & Verified Momentum Stock Watchlist - newser.com
William Blair Keeps Their Buy Rating on Autolus Therapeutics (AUTL) - The Globe and Mail
Autolus Therapeutics’ (AUTL) “Outperform” Rating Reaffirmed at William Blair - Defense World
Income MSTR Etf forming a bottoming basePortfolio Value Report & Risk Adjusted Swing Trade Ideas - newser.com
How institutional ownership impacts Entrada Therapeutics Inc. stock2025 Valuation Update & Daily Chart Pattern Signal Reports - newser.com
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Short Interest Down 32.1% in August - MarketBeat
Bradstreet Holdings Inc. and competitorsJobs Report & Verified Momentum Stock Ideas - newser.com
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives $9.12 Consensus Target Price from Brokerages - MarketBeat
Will Autolus Therapeutics plc Depositary Receipt see short term momentumJobs Report & Community Consensus Trade Signals - newser.com
Quantitative breakdown of The AES Corporation recent movePortfolio Return Report & Consistent Income Trade Ideas - newser.com
Innovative Therapeutics Pipeline Positions Industry For Strong Market Growth - Barchart.com
Should you wait for a breakout in MSP Recovery Inc. Equity Warrant2025 Geopolitical Influence & Advanced Swing Trade Entry Plans - newser.com
Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth15.09.25News - Ariva
How to build a dashboard for TRNS stockEarnings Risk Report & Safe Entry Zone Identification - newser.com
MAI Capital Management Sells 294,460 Shares of Autolus Therapeutics PLC Sponsored ADR $AUTL - MarketBeat
Vident Advisory LLC Buys Shares of 155,504 Autolus Therapeutics PLC Sponsored ADR $AUTL - Defense World
What are the risks of holding FLYY2025 Big Picture & Short-Term Trading Opportunity Alerts - Lancaster City Council
Autolus Therapeutics Q2 Earnings Call Highlights Growth and Challenges - AInvest
Real time pattern detection on World Acceptance Corporation stockJuly 2025 WrapUp & Free Technical Pattern Based Buy Signals - Newser
Aug Macro: What is the next catalyst for The Toronto Dominion BankRate Cut & Reliable Momentum Entry Alerts - خودرو بانک
How to track smart money flows in BNZIJuly 2025 Volume & AI Optimized Trade Strategies - Newser
Affinity Asset Advisors LLC Sells 1,455,000 Shares of Autolus Therapeutics PLC Sponsored ADR $AUTL - MarketBeat
PLOW recovery potential after sell offWeekly Investment Report & Growth Oriented Trading Recommendations - Newser
Price momentum metrics for HIG.PRG explainedMarket Trend Report & Growth Focused Entry Reports - Newser
Analyzing recovery setups for Autolus Therapeutics plc Depositary Receipt investorsRate Hike & High Accuracy Buy Signal Tips - Newser
Applying Elliott Wave Theory to Travel + Leisure Co.July 2025 Rallies & Comprehensive Market Scan Reports - Newser
AUTL’s Market Quandary: Decoding the Ups and Downs of 2025 - investchronicle.com
Can machine learning forecast MNDR recoveryJuly 2025 EndofMonth & Real-Time Sentiment Analysis - Newser
What makes TFIN stock price move sharplyJuly 2025 Macro Moves & Advanced Technical Signal Analysis - Newser
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Average Recommendation of “Buy” by Brokerages - Defense World
Autolus Therapeutics (NASDAQ:AUTL) Sees Strong Trading Volume on Earnings Beat - MarketBeat
Q3 EPS Forecast for Autolus Therapeutics Raised by Analyst - Defense World
Knott David M Jr Makes New $651,000 Investment in Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) - MarketBeat
Wells Fargo & Company Has Lowered Expectations for Autolus Therapeutics (NASDAQ:AUTL) Stock Price - Defense World
Cetera Investment Advisers Raises Stock Position in Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) - Defense World
Critical Analysis: Omni-Lite Industries Canada (OTCMKTS:OLNCF) & Mueller Industries (NYSE:MLI) - Defense World
Autolus Therapeutics (NASDAQ:AUTL) Shares Down 3.5% After Analyst Downgrade - Defense World
Autolus reports $20.9 million in Q2 2025 AUCATZYL revenue - Investing.com India
Will Albertsons Companies Inc. stock recover after recent dropFree Entry and Exit Strategy Optimizer Tool - Newser
Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates - GlobeNewswire Inc.
How GLDD stock performs during market volatilityAlgorithmic Forecast for Swing Trading Picks - Newser
Autolus Therapeutics earnings beat by $0.05, revenue topped estimates - Investing.com UK
Why IGNEP stock attracts strong analyst attentionFree Day Trading Signals With High Precision - Newser
Autolus Therapeutics Plc Adr Stock (AUTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):